Cargando…

Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy

There is a dire need for reliable biomarkers to solidify an early and accurate diagnosis of multiple system atrophy (MSA). We sought to compare the ability of emerging plasma markers in distinguishing MSA from its mimics and healthy controls in early disease stages, and to evaluate their performance...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yu, Shen, Xue-Ning, Huang, Shu-Yi, Chen, Shu-Fen, Wang, Hui-Fu, Zhang, Wei, Zhang, Ya-Ru, Cheng, Wei, Cui, Mei, Dong, Qiang, Yu, Jin-Tai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017699/
https://www.ncbi.nlm.nih.gov/pubmed/36922526
http://dx.doi.org/10.1038/s41531-023-00481-5
_version_ 1784907647105892352
author Guo, Yu
Shen, Xue-Ning
Huang, Shu-Yi
Chen, Shu-Fen
Wang, Hui-Fu
Zhang, Wei
Zhang, Ya-Ru
Cheng, Wei
Cui, Mei
Dong, Qiang
Yu, Jin-Tai
author_facet Guo, Yu
Shen, Xue-Ning
Huang, Shu-Yi
Chen, Shu-Fen
Wang, Hui-Fu
Zhang, Wei
Zhang, Ya-Ru
Cheng, Wei
Cui, Mei
Dong, Qiang
Yu, Jin-Tai
author_sort Guo, Yu
collection PubMed
description There is a dire need for reliable biomarkers to solidify an early and accurate diagnosis of multiple system atrophy (MSA). We sought to compare the ability of emerging plasma markers in distinguishing MSA from its mimics and healthy controls in early disease stages, and to evaluate their performance in detecting disease severity and brain atrophy. Plasma neurofilament light (NfL), glial fibrillary acidic protein (GFAP), phosphorylated tau181, amyloid-β (Aβ)42, and Aβ40 were measured using ultrasensitive Simoa in early-stage patients with MSA (n = 73), spinocerebellar ataxia (SCA, n = 29), Parkinson’s disease (PD, n = 28), and healthy controls (n = 100). We observed that elevated NfL outperformed other biomarkers in distinguishing MSA and its subtypes (AUC = 0.9) versus controls. Intriguingly, when separating MSA from its mimics, increased GFAP (AUC = 0.717) in MSA-C and decreased Aβ40 (AUC = 0.807) in MSA-P best discriminated from SCA and PD respectively. Plasma levels were comparable between MSA-C and MSA-P and the differentiation by plasma index alone was poor. Combining plasma markers noticeably improved the discriminatory efficacy. Of note, among MSA patients, higher GFAP and NfL were correlated with the atrophy of brain regions vulnerable to MSA (e.g., cerebellum, pons, or putamen). They could also aggravate the severity of MSA, and this association was partially mediated by cerebral volumes. In contrast, no obvious associations of phosphorylated tau and Aβ with disease severity were observed. Collectively, plasma biomarkers, especially in combination, are useful to facilitate the discriminatory work-up of MSA at early stages. Moreover, NfL and GFAP may be promising biomarkers to monitor the disease severity of MSA.
format Online
Article
Text
id pubmed-10017699
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-100176992023-03-17 Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy Guo, Yu Shen, Xue-Ning Huang, Shu-Yi Chen, Shu-Fen Wang, Hui-Fu Zhang, Wei Zhang, Ya-Ru Cheng, Wei Cui, Mei Dong, Qiang Yu, Jin-Tai NPJ Parkinsons Dis Article There is a dire need for reliable biomarkers to solidify an early and accurate diagnosis of multiple system atrophy (MSA). We sought to compare the ability of emerging plasma markers in distinguishing MSA from its mimics and healthy controls in early disease stages, and to evaluate their performance in detecting disease severity and brain atrophy. Plasma neurofilament light (NfL), glial fibrillary acidic protein (GFAP), phosphorylated tau181, amyloid-β (Aβ)42, and Aβ40 were measured using ultrasensitive Simoa in early-stage patients with MSA (n = 73), spinocerebellar ataxia (SCA, n = 29), Parkinson’s disease (PD, n = 28), and healthy controls (n = 100). We observed that elevated NfL outperformed other biomarkers in distinguishing MSA and its subtypes (AUC = 0.9) versus controls. Intriguingly, when separating MSA from its mimics, increased GFAP (AUC = 0.717) in MSA-C and decreased Aβ40 (AUC = 0.807) in MSA-P best discriminated from SCA and PD respectively. Plasma levels were comparable between MSA-C and MSA-P and the differentiation by plasma index alone was poor. Combining plasma markers noticeably improved the discriminatory efficacy. Of note, among MSA patients, higher GFAP and NfL were correlated with the atrophy of brain regions vulnerable to MSA (e.g., cerebellum, pons, or putamen). They could also aggravate the severity of MSA, and this association was partially mediated by cerebral volumes. In contrast, no obvious associations of phosphorylated tau and Aβ with disease severity were observed. Collectively, plasma biomarkers, especially in combination, are useful to facilitate the discriminatory work-up of MSA at early stages. Moreover, NfL and GFAP may be promising biomarkers to monitor the disease severity of MSA. Nature Publishing Group UK 2023-03-15 /pmc/articles/PMC10017699/ /pubmed/36922526 http://dx.doi.org/10.1038/s41531-023-00481-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Guo, Yu
Shen, Xue-Ning
Huang, Shu-Yi
Chen, Shu-Fen
Wang, Hui-Fu
Zhang, Wei
Zhang, Ya-Ru
Cheng, Wei
Cui, Mei
Dong, Qiang
Yu, Jin-Tai
Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy
title Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy
title_full Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy
title_fullStr Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy
title_full_unstemmed Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy
title_short Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy
title_sort head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017699/
https://www.ncbi.nlm.nih.gov/pubmed/36922526
http://dx.doi.org/10.1038/s41531-023-00481-5
work_keys_str_mv AT guoyu headtoheadcomparisonof6plasmabiomarkersinearlymultiplesystematrophy
AT shenxuening headtoheadcomparisonof6plasmabiomarkersinearlymultiplesystematrophy
AT huangshuyi headtoheadcomparisonof6plasmabiomarkersinearlymultiplesystematrophy
AT chenshufen headtoheadcomparisonof6plasmabiomarkersinearlymultiplesystematrophy
AT wanghuifu headtoheadcomparisonof6plasmabiomarkersinearlymultiplesystematrophy
AT zhangwei headtoheadcomparisonof6plasmabiomarkersinearlymultiplesystematrophy
AT zhangyaru headtoheadcomparisonof6plasmabiomarkersinearlymultiplesystematrophy
AT chengwei headtoheadcomparisonof6plasmabiomarkersinearlymultiplesystematrophy
AT cuimei headtoheadcomparisonof6plasmabiomarkersinearlymultiplesystematrophy
AT dongqiang headtoheadcomparisonof6plasmabiomarkersinearlymultiplesystematrophy
AT yujintai headtoheadcomparisonof6plasmabiomarkersinearlymultiplesystematrophy